Axsome Therapeutics has received a positive signal from the FDA for its migraine treatment, AXS-07, with the acceptance of its resubmitted New Drug Application (NDA). This news could potentially diversify Axsome’s product portfolio and fuel further growth, alongside its existing products for major depressive disorder and narcolepsy. The FDA’s decision on the approval is expected on January 31, 2025.